| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/17/2009 | WO2009087173A3 Antibody designated barb3, barb3 related antibodies, and methods of making and using same |
| 09/17/2009 | WO2009077462A3 Chiral cycloplatinized complexes, method for the production thereof and their use in medicine and catalysts |
| 09/17/2009 | WO2009071850A8 Nanoparticles of therapeutic agents having low water solubility |
| 09/17/2009 | WO2009068190A3 Combinations comprising a prostaglandin and uses thereof |
| 09/17/2009 | WO2009046867A3 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 09/17/2009 | WO2009046866A3 Trap-14 as a therapeutic agent |
| 09/17/2009 | WO2009040070A3 Use of helodermin as a therapeutic agent |
| 09/17/2009 | WO2009037225A3 Production of leaf extracts of pittosporum phillyraeoides and the use thereof in medicine |
| 09/17/2009 | WO2008084106A9 Anti-kir antibodies, formulations, and uses thereof |
| 09/17/2009 | US20090234105 Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition |
| 09/17/2009 | US20090234103 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 09/17/2009 | US20090234019 T Type Calcium Channel Inhibitors |
| 09/17/2009 | US20090233976 Antimitotic Rhizoxin Deritivatives of Burkholderia Rhizoxina, Method for Producing Said Derivatives and Use Thereof |
| 09/17/2009 | US20090233973 Epothilone derivatives for the treatment of multiple myeloma |
| 09/17/2009 | US20090233971 GSK-3 Inhibitors |
| 09/17/2009 | US20090233956 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS |
| 09/17/2009 | US20090233937 Fused heterocyclic compound |
| 09/17/2009 | US20090233926 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| 09/17/2009 | US20090233923 Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof |
| 09/17/2009 | US20090233915 mitogen-activated protein kinase inhibitors such as 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5(2-hydroxy-ethoxymethyl)-benzamide, used to treat proliferative diseases, for example, cancers, psoriasis, restenosis, autoimmune diseases and atherosclerosis |
| 09/17/2009 | US20090233905 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 09/17/2009 | US20090233903 Azetidine and cyclobutane derivatives as jak inhibitors |
| 09/17/2009 | US20090233902 Indolopyridines as eg5 kinesin modulators |
| 09/17/2009 | US20090233896 Inhibitors of checkpoint kinases |
| 09/17/2009 | US20090233894 Compounds and Methods For The Treatment of Cancer |
| 09/17/2009 | US20090233880 Equol production accelerating composition |
| 09/17/2009 | US20090233878 Novel adenosine a3 receptor agonists |
| 09/17/2009 | US20090233876 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives |
| 09/17/2009 | US20090233855 Compounds and methods for modulating activation of nf-kb |
| 09/17/2009 | US20090233849 Recombinant Alpha-Fetoprotein, Method and Means for Preparation Thereof, Compositions on the Base Thereof and Use Thereof |
| 09/17/2009 | US20090233848 Pea15 as a Tumor Suppressor Gene |
| 09/17/2009 | US20090233813 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors |
| 09/17/2009 | US20090233803 Chromogenic in situ hybridization methods, kits, and compositions |
| 09/17/2009 | US20090232906 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| 09/17/2009 | US20090232882 PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER |
| 09/17/2009 | US20090232832 Polyclonal antiserum against a universal tumor antigen |
| 09/17/2009 | US20090232828 Methods of Using IGFIR and ABL Kinase Modulators |
| 09/17/2009 | US20090232827 Compositions and methods of use of compounds to increase cancer patient survival time |
| 09/17/2009 | US20090232823 Anti-tyrp1 antibodies |
| 09/17/2009 | US20090232822 Lung disease targets and uses thereof |
| 09/17/2009 | US20090232817 Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| 09/17/2009 | US20090232812 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/17/2009 | US20090232810 Immunoconjugates targeting cd138 and uses thereof |
| 09/17/2009 | US20090232787 Carcinogen detoxification composition and method |
| 09/17/2009 | US20090232786 Herbal composition for cancer treatment |
| 09/17/2009 | US20090232768 Novel compounds and methods for therapy |
| 09/17/2009 | US20090232767 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| 09/17/2009 | US20090232766 Compositions for Inducing Immune Response Comprising Inverted Microsomes |
| 09/17/2009 | US20090232740 Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease |
| 09/17/2009 | US20090232735 Use of fructose-based therapies for the treatment of cancer |
| 09/17/2009 | US20090232734 Anti-tissue factor antibodies and compositions |
| 09/17/2009 | US20090232732 PRO108 Antibody Compositions and Methods of Use and Use of PRO108 to Assess Cancer Risk |
| 09/17/2009 | DE102008014077A1 New borrelidin derivatives are janus kinase 3 inhibitors useful e.g. for treating tumor, microbial infection, immune disorder and ophthalmic disease, inhibiting angiogenesis, and manufacturing herbicides and insecticides against arthropods |
| 09/17/2009 | DE102008013622A1 Pharmazeutische Zusammensetzung zur Diagnose oder Behandlung des Plasmozytoms A pharmaceutical composition for the diagnosis or treatment of multiple myeloma |
| 09/17/2009 | CA2734208A1 Mitochondrially delivered anti-cancer compounds |
| 09/17/2009 | CA2727792A1 Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action |
| 09/17/2009 | CA2719074A1 Novel method for the production of sulphonylpyrroles as hdac inhibitors |
| 09/17/2009 | CA2719071A1 (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide salts |
| 09/17/2009 | CA2718499A1 Antibody against the csf-1 r |
| 09/17/2009 | CA2718400A1 Piperlongumine and piperlongumine analogs for use in the treatment of cancer |
| 09/17/2009 | CA2718382A1 C2orf18 as target gene for cancer therapy and diagnosis |
| 09/17/2009 | CA2718289A1 Anti-tyrp1 antibodies |
| 09/17/2009 | CA2718271A1 Azetidine and cyclobutane derivatives as jak inhibitors |
| 09/17/2009 | CA2718252A1 Bicyclic pyrrole compound |
| 09/17/2009 | CA2718153A1 Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same |
| 09/17/2009 | CA2717904A1 Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
| 09/17/2009 | CA2717488A1 Thiazolyl-dihydro-indazoles |
| 09/17/2009 | CA2717169A1 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| 09/17/2009 | CA2716079A1 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| 09/17/2009 | CA2715036A1 Therapies for cancer using isotopically substituted lysine |
| 09/17/2009 | CA2710801A1 2-benzoyl-imidazo(1,2-.alpha) pyridine derivatives, their preparation and their therapeutic application |
| 09/17/2009 | CA2710797A1 Imidazo[1,2-.alpha.]pyridine-2-carboxamide derivatives, preparation thereof and application thereof in therapeutics |
| 09/16/2009 | EP2100894A1 Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| 09/16/2009 | EP2100891A1 Inhibitors of tyrosine kinases |
| 09/16/2009 | EP2100882A1 (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts |
| 09/16/2009 | EP2100879A1 Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| 09/16/2009 | EP2100878A1 Novel method for the production of sulphonylpyrroles as HDAC inhibitors |
| 09/16/2009 | EP2100876A2 New compounds for the inhibition of rotamases and use thereof |
| 09/16/2009 | EP2100620A1 Nucleic acids encoding polyepitope polypeptides |
| 09/16/2009 | EP2100619A1 Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 09/16/2009 | EP2100618A2 PDGFR-alpha antagonists for treatment of metastatic bone cancer |
| 09/16/2009 | EP2100617A1 Methods of modulating CD200 receptors |
| 09/16/2009 | EP2100616A2 Composition of antigen and glycolipid adjuvant sublingual administration |
| 09/16/2009 | EP2100615A1 Cancer therapy |
| 09/16/2009 | EP2100614A2 PDGFR-alpha antagonists for treatment of metastatic bone cancer |
| 09/16/2009 | EP2100605A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer |
| 09/16/2009 | EP2100603A1 Use of malachite green in the form of drug for treating malignant neoplasms |
| 09/16/2009 | EP2099827A2 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| 09/16/2009 | EP2099823A2 Variant target binding agents and uses thereof |
| 09/16/2009 | EP2099803A1 Heterobicyclic matrix metalloprotease inhibitors |
| 09/16/2009 | EP2099797A2 Compounds and compositions as protein kinase inhibitors |
| 09/16/2009 | EP2099796A1 Aza-indolyl compounds and methods of use |
| 09/16/2009 | EP2099776A1 Chelating agent |
| 09/16/2009 | EP2099770A2 Pyridazinones and furan-containing compounds |
| 09/16/2009 | EP2099757A2 Sulfoximines as kinase inhibitors |
| 09/16/2009 | EP2099489A2 Compositions and methods for treating a neoplasm |
| 09/16/2009 | EP2099470A1 Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer |
| 09/16/2009 | EP2099461A2 Lna nucleoside phosphoramidates |
| 09/16/2009 | EP2099460A2 6-alkoxyalkyl estradiol derivatives and methods of use |
| 09/16/2009 | EP2099451A2 Combination of an hdac inhibitor and an antimetabolite |